Respiratory medicines for children: current evidence, unlicensed use and research priorities

Keyphrases

• Unlicensed Use 100%
• Respiratory Medicine 100%
• Neuromuscular Disorders 100%
• Medicines for children 100%
• Off-licence 100%
• Asthma 50%
• Pneumonia 50%
• Pharmaceutical Industry 50%
• Antibiotics 50%
• European Medicines Agency 50%
• Muscle Strength 50%
• Cystic Fibrosis 50%
• Antibiotic Prophylaxis 50%
• Immunoglobulin 50%
• Rapid Diagnostic Test 50%
• Pleural Infection 50%
• Pulmonary Abnormalities 50%
• Novel Regimens 50%
• Immune Deficiency 50%
• Primary Ciliary Dyskinesia 50%
• Antifungal Drugs 50%
• Novel Formulations 50%
• New Antibacterials 50%
• European Respiratory Society 50%
• Basic Defect 50%
• Antibiotic Surveillance 50%
• Paediatric Committee 50%
• Antibiotic Penetration 50%
• Dornase Alfa 50%
• β-agonists 50%
• Off-label Use 50%
• Respiratory Disease 50%
• Pediatric Medicine 50%
• New Regimens 50%
• Lay Public 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Neuromuscular Disease 100%
• Antimicrobial Agent 100%
• Antiinfective Agent 50%
• Infection 50%
• Asthma 50%
• Cystic Fibrosis 50%
• Antibiotic Prophylaxis 50%
• Fibrinolytic Agent 50%
• Immunoglobulin 50%
• Dornase Alfa 50%
• Off-Label Use 50%
• Respiratory Tract Disease 50%
• Beta Adrenergic Receptor Stimulating Agent 50%
• Antifungal Agent 50%
• Immune Deficiency 50%
• Ciliary Dyskinesia 50%
• Novel Formulation 50%
• Enzymes 50%
• Pneumonia 50%